

I. AMENDMENTS TO THE CLAIMS:

1-10. (Canceled)

11. (Currently Amended) A method of treating psoriasis affected area of the skin, scalp or nails comprising the steps of:

- a) orally administering to a psoriasis affected individual a composition comprising about 400 mg boswellic acid₁ [[and]] about 100 micrograms of selenomethionine, a selenium compound and a pharmaceutically acceptable carrier three times per day; and
- b) topically applying to the affected area a composition [[of]] comprising 5% w/w Boswellia serrata extract comprising boswellic acid₁ and a pharmaceutically acceptable carrier three times per day.

12. (Previously Presented) The method of claim 11, wherein the orally administered composition contains about 400 mg of boswellic acid represented by one or more of the following groups:

- a) beta-boswellic acid, acetyl beta-boswellic acid, 11-keto beta-boswellic acid, acetyl-11-keto-beta-boswellic acid, as a single entities or mixtures; and
- b) congeners or derivatives of beta-boswellic acid, acetyl beta-boswellic acid, 11-keto beta-boswellic acid, acetyl-11-keto-beta-boswellic acid, as single entities or mixtures.

13. (Canceled)

14. (Currently Amended) The method of claim 11, wherein the topically administered composition contains about 400 mg of boswellic acid represented by one or more of the following groups:

a) beta-boswellic acid, acetyl beta-boswellic acid, 11-keto beta-boswellic acid, acetyl-11-keto-beta-boswellic acid, as [[a]] single entities or mixtures; and

b) congeners or derivatives of beta-boswellic acid, acetyl beta-boswellic acid, 11-keto beta-boswellic acid, acetyl-11-keto-beta-boswellic acid, as single entities or mixtures.

15. (Previously Presented) The method of claim 11, wherein the orally administered composition contains about 400 mg of acetyl-11-keto-beta-boswellic acid.

16. (Currently Amended) The method of claim 11, wherein the orally administered composition contains about 100 micrograms of selenium from Selenomethionine is L(+)-Selenomethionine.

17. (Previously Presented) The method of claim 11, wherein the topically administered composition contains about 400 mg of acetyl-11-keto-beta-boswellic acid.

18. (Canceled)

19. (Canceled)

20. (Previously Presented) The method of claim 11, wherein the total daily topical dose of boswellic acid is about 1200 mg, administered in a plurality of individual doses.

21. (New) A method of treating psoriasis affected area of the skin, scalp or nails comprising the steps of:

- a) orally administering to a psoriasis affected individual a composition comprising about 400 mg boswellic acid, about 100 micrograms of elemental selenium, and a pharmaceutically acceptable carrier, three times per day; and
- b) topically applying to the affected area a composition comprising 5% w/w *Boswellia serrata* extract comprising boswellic acid, and a pharmaceutically acceptable carrier three times per day.

22. (New) The method of claim 22, wherein the elemental selenium is in the form of one or more of the following selenium sources: selenomethionine, Se-methylselenocysteine, derivatives of selenomethionine, derivatives of Se-methylselenocysteine, and high selenium yeast.

23. (New) A method of treating psoriasis affected area of the skin, scalp or nails comprising the steps of:

- a) orally administering to a psoriasis affected individual a composition comprising about 400 mg boswellic acid, about 100 micrograms of elemental selenium in the form of one or more of the following selenium sources: selenomethionine, Se-methylselenocysteine,

derivatives of selenomethionine, derivatives of Se-methylselenocysteine, and a pharmaceutically acceptable carrier, three times per day; and

b) topically applying to the affected area a composition comprising 5% w/w *Boswellia serrata* extract comprising boswellic acid, and a pharmaceutically acceptable carrier three times per day.

24. (New) A method of treating psoriasis affected area of the skin, scalp or nails comprising the steps of:

a) orally administering to a psoriasis affected individual a composition comprising about 400 mg boswellic acid, about 100 micrograms of elemental selenium in the form of high selenium yeast, and a pharmaceutically acceptable carrier, three times per day; and

b) topically applying to the affected area a composition comprising 5% w/w *Boswellia serrata* extract comprising boswellic acid, and a pharmaceutically acceptable carrier three times per day.